BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36497231)

  • 1. Adenosine 2A Receptor Activation Amplifies Ibrutinib Antiplatelet Effect; Implications in Chronic Lymphocytic Leukemia.
    Elaskalani O; Gilmore G; Hagger M; Baker RI; Metharom P
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
    Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
    Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
    Dmitrieva EA; Nikitin EA; Ignatova AA; Vorobyev VI; Poletaev AV; Seregina EA; Voronin KA; Polokhov DM; Maschan AA; Novichkova GA; Panteleev MA; Ptushkin VV
    J Thromb Haemost; 2020 Oct; 18(10):2672-2684. PubMed ID: 32511880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
    Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function.
    Zheng TJ; Lofurno ER; Melrose AR; Lakshmanan HHS; Pang J; Phillips KG; Fallon ME; Kohs TCL; Ngo ATP; Shatzel JJ; Hinds MT; McCarty OJT; Aslan JE
    Am J Physiol Cell Physiol; 2021 May; 320(5):C902-C915. PubMed ID: 33689480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function.
    Tullemans BME; Karel MFA; Léopold V; Ten Brink MS; Baaten CCFMJ; Maas SL; de Vos AF; Eble JA; Nijziel MR; van der Vorst EPC; Cosemans JMEM; Heemskerk JWM; Claushuis TAM; Kuijpers MJE
    EJHaem; 2021 Nov; 2(4):685-699. PubMed ID: 35845214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.
    Cheng S; Ma J; Guo A; Lu P; Leonard JP; Coleman M; Liu M; Buggy JJ; Furman RR; Wang YL
    Leukemia; 2014 Mar; 28(3):649-57. PubMed ID: 24270740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans.
    Dobie G; Kuriri FA; Omar MMA; Alanazi F; Gazwani AM; Tang CPS; Sze DM; Handunnetti SM; Tam C; Jackson DE
    Blood Adv; 2019 Dec; 3(24):4298-4311. PubMed ID: 31869418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
    Liu TM; Woyach JA; Zhong Y; Lozanski A; Lozanski G; Dong S; Strattan E; Lehman A; Zhang X; Jones JA; Flynn J; Andritsos LA; Maddocks K; Jaglowski SM; Blum KA; Byrd JC; Dubovsky JA; Johnson AJ
    Blood; 2015 Jul; 126(1):61-8. PubMed ID: 25972157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
    Reiff SD; Muhowski EM; Guinn D; Lehman A; Fabian CA; Cheney C; Mantel R; Smith L; Johnson AJ; Young WB; Johnson AR; Liu L; Byrd JC; Woyach JA
    Blood; 2018 Sep; 132(10):1039-1049. PubMed ID: 30018078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.
    Bose P; Gandhi VV; Keating MJ
    Expert Opin Drug Metab Toxicol; 2016 Nov; 12(11):1381-1392. PubMed ID: 27686109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Btk inhibitor AB-95-LH34 potently inhibits atherosclerotic plaque-induced thrombus formation and platelet procoagulant activity.
    Smith CW; Harbi MH; Garcia-Quintanilla L; Rookes K; Brown H; Poulter NS; Watson SP; Nicolson PLR; Thomas MR
    J Thromb Haemost; 2022 Dec; 20(12):2939-2952. PubMed ID: 36239466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.
    Bye AP; Unsworth AJ; Vaiyapuri S; Stainer AR; Fry MJ; Gibbins JM
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2326-35. PubMed ID: 26359510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib.
    Bye AP; Unsworth AJ; Desborough MJ; Hildyard CAT; Appleby N; Bruce D; Kriek N; Nock SH; Sage T; Hughes CE; Gibbins JM
    Blood Adv; 2017 Dec; 1(26):2610-2623. PubMed ID: 29296914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans.
    Busygina K; Jamasbi J; Seiler T; Deckmyn H; Weber C; Brandl R; Lorenz R; Siess W
    Blood; 2018 Jun; 131(24):2605-2616. PubMed ID: 29559479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction.
    Ninomoto J; Mokatrin A; Kinoshita T; Marimpietri C; Barrett TD; Chang BY; Sukbuntherng J; James DF; Crowther M
    Hematology; 2020 Dec; 25(1):112-117. PubMed ID: 32131714
    [No Abstract]   [Full Text] [Related]  

  • 18. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
    Reiff SD; Mantel R; Smith LL; Greene JT; Muhowski EM; Fabian CA; Goettl VM; Tran M; Harrington BK; Rogers KA; Awan FT; Maddocks K; Andritsos L; Lehman AM; Sampath D; Lapalombella R; Eathiraj S; Abbadessa G; Schwartz B; Johnson AJ; Byrd JC; Woyach JA
    Cancer Discov; 2018 Oct; 8(10):1300-1315. PubMed ID: 30093506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.
    Series J; Garcia C; Levade M; Viaud J; Sié P; Ysebaert L; Payrastre B
    Haematologica; 2019 Nov; 104(11):2292-2299. PubMed ID: 30819914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noncatalytic Bruton's tyrosine kinase activates PLCγ
    Wist M; Meier L; Gutman O; Haas J; Endres S; Zhou Y; Rösler R; Wiese S; Stilgenbauer S; Hobeika E; Henis YI; Gierschik P; Walliser C
    J Biol Chem; 2020 Apr; 295(17):5717-5736. PubMed ID: 32184360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.